| Politician | Action | Description | Traded |
|---|---|---|---|
| Buy | Abbott Laboratories Common S | Sep 18, 2026 | |
| Buy | ABBOTT LABORATORIES CMN | Sep 4, 2026 | |
| Sell | Abbott Laboratories Common S | Jul 30, 2026 | |
| Sell | Abbott Laboratories Common S | Jul 17, 2026 | |
| Sell | Abbott Laboratories Common S | Jul 14, 2026 | |
| Sell | Abbott Laboratories Common S | Jul 8, 2026 | |
| Buy | ABBOTT LABORATORIES | Jun 23, 2026 | |
| Buy | ABBOTT LABORATORIES | Jun 23, 2026 | |
| Buy | Abbott Laboratories Common S | Jun 16, 2026 | |
| Buy | Abbott Laboratories Common S | Jun 12, 2026 |
This page tracks congressional stock trading activity in Abbott Laboratories (ABT) in the Healthcare sector. Disclosed Capitol has indexed 364 disclosed congressional trades involving ABT. Every trade is sourced from official STOCK Act financial disclosure filings — the same primary records the Senate and House are required to publish. The full trade list with politician names, transaction types, amount ranges, and disclosure dates is below, alongside cross-references to any related lobbying activity, federal contracts, and committee assignments.
As of October 2026 — Disclosed Capitol has tracked 364 disclosed congressional trades in Abbott Laboratories (ABT) — 194:155 buy-heavy ratio — led by Ro Khanna (D).
| Date | Politician | Party | Action | Amount |
|---|---|---|---|---|
| Sep 18, 2026 | Gilbert Cisneros | D | Buy | $1,001 - $15,000 |
| Sep 4, 2026 | Ro Khanna | D | Buy | $1,001 - $15,000 |
| Jul 30, 2026 | Richard Dean Dr McCormick | R | Sell | $1,001 - $15,000 |
| Jul 17, 2026 | Mike Kelly | R | Sell | $1,001 - $15,000 |
| Jul 14, 2026 | Richard W. Allen | R | Sell | $15,001 - $50,000 |
| Jul 8, 2026 | Rick Larsen | D | Sell | $1,001 - $15,000 |
| Jun 23, 2026 | Ro Khanna | D | Buy | $1,001 - $15,000 |
| Jun 23, 2026 | Ro Khanna | D | Buy | $1,001 - $15,000 |
| Jun 16, 2026 | Gilbert Cisneros | D | Buy | $1,001 - $15,000 |
| Jun 12, 2026 | Richard Dean Dr McCormick | R | Buy | $1,001 - $15,000 |
Across the 364 disclosed congressional trades in Abbott Laboratories (ABT), members of Congress have reported 194 buys and 155 sells. The average 30-day alpha vs. the S&P 500 is -0.80%.
As of October 2026, Abbott Laboratories has 3,360 federal contract award records on file from USAspending.gov — most recently $334K from the Department of Veterans Affairs on 2026-10-07.
| Award date | Agency | Amount |
|---|---|---|
| 2026-10-07 | Department of Veterans Affairs | $334K |
| 2026-10-02 | Department of Veterans Affairs | $1.9M |
| 2026-10-02 | Department of Veterans Affairs | $1.4M |
| 2026-10-02 | Department of Veterans Affairs | $1.9M |
| 2026-10-02 | Department of Veterans Affairs | $1.4M |
| 2026-10-01 | Department of Veterans Affairs | $2.9M |
| 2026-10-01 | Department of Veterans Affairs | $2.1M |
| 2026-10-01 | Department of Veterans Affairs | $1.9M |
| 2026-10-01 | Department of Veterans Affairs | $1.6M |
| 2026-10-01 | Department of Veterans Affairs | $1.6M |
Negative amounts are contract de-obligations. Browse and filter every award on the government contracts page.
For fiscal year 2025, Abbott Laboratories reported revenue of $44.33B and net income of $6.52B, per SEC filings.
Most recent reported quarter: Q1 FY2026 — revenue $11.16B, net income $1.08B.
Figures come from SEC financial statement filings. The full annual and quarterly statement history is in the Financials tab above.